ATE305932T1 - Rapanycin29-enole - Google Patents

Rapanycin29-enole

Info

Publication number: ATE305932T1
Authority: AT; Austria
Prior art keywords: enole; enols; useful; treatment; solid tumors
Prior art date: 2001-08-22

Application number

AT02768642T

Other languages

English (en)

Inventor

Tianmin Zhu

Mahdi Bakir Fawzi

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-22

Filing date

2002-08-21

Publication date

2005-10-15

2002-08-21 Application filed by Wyeth Corp filed Critical Wyeth Corp

2005-10-15 Application granted granted Critical

2005-10-15 Publication of ATE305932T1 publication Critical patent/ATE305932T1/de

Links

206010028980 Neoplasm Diseases 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
230000000508 neurotrophic effect Effects 0.000 abstract 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
229960002930 sirolimus Drugs 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Pharmacology & Pharmacy (AREA)
Neurology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)

AT02768642T 2001-08-22 2002-08-21 Rapanycin29-enole ATE305932T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31421101P	2001-08-22	2001-08-22
PCT/US2002/026622 WO2003018573A1 (en)	2001-08-22	2002-08-21	Rapamycin 29-enols

Publications (1)

Publication Number	Publication Date
ATE305932T1 true ATE305932T1 (de)	2005-10-15

Family

ID=23219037

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02768642T ATE305932T1 (de)	2001-08-22	2002-08-21	Rapanycin29-enole

Country Status (12)

Country	Link
US (1)	US6677357B2 (de)
EP (1)	EP1419154B1 (de)
JP (1)	JP2005501868A (de)
CN (1)	CN1310908C (de)
AT (1)	ATE305932T1 (de)
BR (1)	BR0211986A (de)
CA (1)	CA2455308A1 (de)
DE (1)	DE60206512T2 (de)
DK (1)	DK1419154T3 (de)
ES (1)	ES2246409T3 (de)
MX (1)	MXPA04001524A (de)
WO (1)	WO2003018573A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60231868D1 (de) *	2001-04-24	2009-05-20	Purdue Research Foundation	Folat-mimetika und deren folatrezeptorbindende konjugate
US20030176455A1 (en) *	2002-03-13	2003-09-18	Wyeth	Method of inhibiting cell death
CA2484640C (en) *	2002-05-15	2012-01-17	Endocyte, Inc.	Vitamin-mitomycin conjugates
RU2344821C2 (ru)	2002-07-30	2009-01-27	Уайт	Парентеральные композиции, содержащие гидроксиэфиры рапамицина
EP2517729A3 (de)	2003-01-27	2013-01-02	Endocyte, Inc.	Vitaminrezeptorbindende Wirkstofffreisetzungskonjugate
US20070155771A1 (en) *	2003-04-11	2007-07-05	David Rubinsztein	Methods and means for treating protein conformational disorders
US7349971B2 (en) *	2004-02-05	2008-03-25	Scenera Technologies, Llc	System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
JP5149620B2 (ja)	2004-07-23	2013-02-20	エンドサイト，インコーポレイテッド	２価リンカーおよびその結合体
US8313763B2 (en)	2004-10-04	2012-11-20	Tolmar Therapeutics, Inc.	Sustained delivery formulations of rapamycin compounds
CA2582374A1 (en) *	2004-10-04	2006-04-20	Qlt Usa, Inc.	Ocular delivery of polymeric delivery formulations
US8021849B2 (en)	2004-11-05	2011-09-20	Siemens Healthcare Diagnostics Inc.	Methods and kits for the determination of sirolimus in a sample
US7632307B2 (en) *	2004-12-16	2009-12-15	Advanced Cardiovascular Systems, Inc.	Abluminal, multilayer coating constructs for drug-delivery stents
US7273874B2 (en)	2004-12-20	2007-09-25	Wyeth	Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
WO2006068932A2 (en)	2004-12-20	2006-06-29	Wyeth	Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
BRPI0607932A2 (pt)	2005-02-09	2016-11-08	Wyeth Corp	polimorfo cci-779, processo para preparar polimorfo cci-779, composição farmacêutica, kit, e método para preparar uma composição farmacêutica
WO2006096325A1 (en) *	2005-03-07	2006-09-14	Wyeth	Oxepane isomer of 42-o-(2-hydroxy)ethyl-rapamycin
JP2008537543A (ja) *	2005-03-07	2008-09-18	ノバルティスアクチエンゲゼルシャフト	神経変性状態に関与する遺伝子
CN101175757B (zh) *	2005-03-16	2012-11-14	恩多塞特公司	蝶酸及其缀合物的合成和纯化
NZ563003A (en) *	2005-04-27	2011-03-31	Univ Florida	Use of a farnesyl transferase inhibitor to enhance autophagic protein degradation in protein conformation disorders
US7189582B2 (en) *	2005-04-27	2007-03-13	Dade Behring Inc.	Compositions and methods for detection of sirolimus
KR20130113543A (ko) *	2005-08-19	2013-10-15	엔도사이트, 인코포레이티드	복수-약제 리간드 공액체
US20080280937A1 (en) *	2005-08-19	2008-11-13	Christopher Paul Leamon	Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
AR058561A1 (es) *	2005-12-20	2008-02-13	Wyeth Corp	Control de la estabilidad de la forma de dosificacion de cci -779 a traves del control de impurezas de sustancias de farmaco
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080175887A1 (en)	2006-11-20	2008-07-24	Lixiao Wang	Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414526B2 (en) *	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
WO2008101231A2 (en) *	2007-02-16	2008-08-21	Endocyte, Inc.	Methods and compositions for treating and diagnosing kidney disease
CN101678124A (zh) *	2007-03-14	2010-03-24	恩多塞特公司	结合配体连接的微管溶素递药缀合物
JP2008305262A (ja) *	2007-06-08	2008-12-18	Konica Minolta Business Technologies Inc	サーバ及びシンクライアント環境でのプリンタ紹介方法
US9877965B2 (en)	2007-06-25	2018-01-30	Endocyte, Inc.	Vitamin receptor drug delivery conjugates for treating inflammation
CN101784565B (zh)	2007-06-25	2014-12-10	恩多塞特公司	含有亲水性间隔区接头的共轭物
EP2209374B1 (de)	2007-10-25	2014-12-03	Endocyte, Inc.	Tubulysine und verfahren zu ihrer herstellung
WO2010024898A2 (en)	2008-08-29	2010-03-04	Lutonix, Inc.	Methods and apparatuses for coating balloon catheters
PT2365802T (pt)	2008-11-11	2017-11-14	Univ Texas	Microcápsulas de rapamicina e utilização para o tratamento de cancro
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
WO2013013708A1 (en)	2011-07-26	2013-01-31	Fundació Institut D'investigació Biomèdica De Bellvitge	Treatment of acute rejection in renal transplant
EP2589383A1 (de)	2011-11-06	2013-05-08	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin	FKBP-subtypspezifisches Rapamycin-Analogon zur Verwendung bei der Behandlung von Erkrankungen
WO2013126797A1 (en)	2012-02-24	2013-08-29	Purdue Research Foundation	Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en)	2012-03-29	2014-03-20	Endocyte, Inc.	Processes for preparing tubulysin derivatives and conjugates thereof
CN103705925B (zh)	2012-09-29	2018-03-30	段磊	抑制PI3K/AKT/mTOR信号通路的药物组合
US9750728B2 (en)	2012-09-29	2017-09-05	Targeted Therapeutics, Llc	Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
US20150290176A1 (en)	2012-10-12	2015-10-15	The Board Of Regents Of The University Of Texas System	Use of mtor inhibitors to treat vascular cognitive impairment
CN104869998A (zh)	2012-10-16	2015-08-26	恩多塞特公司	含有非天然氨基酸的药物递送缀合物以及其使用方法
EP2968281B1 (de)	2013-03-13	2020-08-05	The Board of Regents of The University of Texas System	Mtor-hemmer zur vorbeugung von darmpolypenwachstum
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
DK3089737T3 (da)	2013-12-31	2021-12-13	Rapamycin Holdings Llc	Orale rapamycin-nanopartikelpræparater og anvendelse.
CA2968049A1 (en)	2014-04-16	2015-10-22	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
CN114949250A (zh)	2016-04-14	2022-08-30	斯宾纳克生物科学公司	用于递送治疗剂的组合物、药物组合物、制备方法以及用途
EP3624863B1 (de)	2017-05-15	2021-04-14	C.R. Bard, Inc.	Medizinische vorrichtung mit wirkstofffreisetzender beschichtung und zwischenschicht
JP7262581B2 (ja)	2018-11-14	2023-04-21	ルトニックス，インコーポレーテッド	改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
JP7487228B2 (ja)	2019-04-08	2024-05-20	バード・ペリフェラル・バスキュラー・インコーポレーテッド	改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US3993749A (en)	1974-04-12	1976-11-23	Ayerst Mckenna And Harrison Ltd.	Rapamycin and process of preparation
US5206018A (en)	1978-11-03	1993-04-27	Ayerst, Mckenna & Harrison, Inc.	Use of rapamycin in treatment of tumors
US4885171A (en)	1978-11-03	1989-12-05	American Home Products Corporation	Use of rapamycin in treatment of certain tumors
US4401653A (en)	1981-03-09	1983-08-30	Ayerst, Mckenna & Harrison Inc.	Combination of rapamycin and picibanil for the treatment of tumors
EP0378318A1 (de) *	1989-01-11	1990-07-18	Merck & Co. Inc.	Verfahren zur Herstellung von FK-506 sowie Tricarbonylzwischenprodukten
US5100899A (en)	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
GB2247456A (en) *	1990-09-03	1992-03-04	Fujisawa Pharmaceutical Co	Tetrahydropyrane compounds, a process for their production and a pharmaceutical composition containing the same
US5078999A (en)	1991-02-22	1992-01-07	American Home Products Corporation	Method of treating systemic lupus erythematosus
US5080899A (en)	1991-02-22	1992-01-14	American Home Products Corporation	Method of treating pulmonary inflammation
US5321009A (en)	1991-04-03	1994-06-14	American Home Products Corporation	Method of treating diabetes
ES2084940T3 (es)	1991-06-18	1996-05-16	American Home Prod	Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas.
ZA924953B (en)	1991-07-25	1993-04-28	Univ Louisville Res Found	Method of treating ocular inflammation
US5286730A (en)	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory disease
US5286731A (en)	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory bowel disease
US5516781A (en)	1992-01-09	1996-05-14	American Home Products Corporation	Method of treating restenosis with rapamycin
US5288711A (en)	1992-04-28	1994-02-22	American Home Products Corporation	Method of treating hyperproliferative vascular disease
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5621108A (en) *	1994-12-05	1997-04-15	Trustees Of The University Of Pennsylvania	Processes and intermediates for preparing macrocycles
US5563145A (en) *	1994-12-07	1996-10-08	American Home Products Corporation	Rapamycin 42-oximes and hydroxylamines
US5561138A (en)	1994-12-13	1996-10-01	American Home Products Corporation	Method of treating anemia
US5496832A (en)	1995-03-09	1996-03-05	American Home Products Corporation	Method of treating cardiac inflammatory disease
EP0927182A2 (de) *	1996-09-09	1999-07-07	American Home Products Corporation	Alkylierte rapamycinderivate
US6002008A (en)	1997-04-03	1999-12-14	American Cyanamid Company	Substituted 3-cyano quinolines
US6277983B1 (en)	2000-09-27	2001-08-21	American Home Products Corporation	Regioselective synthesis of rapamycin derivatives
CA2455311A1 (en)	2001-08-22	2003-03-06	Wyeth	Rapamycin dialdehydes

2002
- 2002-08-21 WO PCT/US2002/026622 patent/WO2003018573A1/en not_active Ceased
- 2002-08-21 ES ES02768642T patent/ES2246409T3/es not_active Expired - Lifetime
- 2002-08-21 CN CNB028163052A patent/CN1310908C/zh not_active Expired - Fee Related
- 2002-08-21 JP JP2003523235A patent/JP2005501868A/ja active Pending
- 2002-08-21 CA CA002455308A patent/CA2455308A1/en not_active Withdrawn
- 2002-08-21 MX MXPA04001524A patent/MXPA04001524A/es active IP Right Grant
- 2002-08-21 BR BR0211986-2A patent/BR0211986A/pt not_active IP Right Cessation
- 2002-08-21 AT AT02768642T patent/ATE305932T1/de not_active IP Right Cessation
- 2002-08-21 DK DK02768642T patent/DK1419154T3/da active
- 2002-08-21 DE DE60206512T patent/DE60206512T2/de not_active Expired - Fee Related
- 2002-08-21 EP EP02768642A patent/EP1419154B1/de not_active Expired - Lifetime
- 2002-08-22 US US10/224,971 patent/US6677357B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2003018573A1 (en)	2003-03-06
CN1310908C (zh)	2007-04-18
US20030114477A1 (en)	2003-06-19
DK1419154T3 (da)	2006-01-09
EP1419154A1 (de)	2004-05-19
US6677357B2 (en)	2004-01-13
ES2246409T3 (es)	2006-02-16
CN1545511A (zh)	2004-11-10
CA2455308A1 (en)	2003-03-06
DE60206512D1 (de)	2006-02-16
MXPA04001524A (es)	2004-05-31
DE60206512T2 (de)	2006-06-22
BR0211986A (pt)	2004-09-28
JP2005501868A (ja)	2005-01-20
EP1419154B1 (de)	2005-10-05

Legal Events

Date	Code	Title	Description
2006-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60206512D1 (de)	2006-02-16	Rapanycin29-enole
MXPA04001523A (es)	2004-05-31	Dialdehidos de rapamicina.
DE50306232D1 (de)	2007-02-15	Ampholytisches copolymer und dessen verwendung
WO2002026746A3 (en)	2002-08-15	1-oxorapamycins
YU9404A (sh)	2006-08-17	Multimerna, usmerena kontrastna sredstva na bazi peptida
SG149063A1 (en)	2009-01-29	Use of modified cyclosporins for the treatment of hcv disorders
NO20034056D0 (no)	2003-09-12	Proliferative sykdommer
CO5611160A2 (es)	2006-02-28	Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
DE60136200D1 (de)	2008-11-27	Wasserlösliche rapamycin-ester
DE60137337D1 (de)	2009-02-26	Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
WO2002028867A3 (en)	2002-08-29	Ethers of 7-desmethylrapamycin for use in immunosuppression
BRPI0307673A2 (pt)	2016-11-08	métodos de tratar doença vascular.
EP1432714A4 (de)	2005-10-19	Chemische verbindungen
WO2002028866A3 (en)	2002-08-15	Hydroxyesters of 7-desmethylrapamycin
WO2001098317A3 (en)	2002-09-26	Alpha-glycosylceramides for treating bacterial and fungal infections
DK1560812T3 (da)	2006-09-04	Aminocyclohexyletherforbindelser og anvendelser deraf
WO2004031129A3 (en)	2004-07-15	Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
WO2004041158A3 (en)	2004-07-15	Rifalazil compositions and therapeutic regimens
WO2003051299A8 (en)	2004-04-22	Sulfhydryl rifamycins and uses thereof
WO2004045545A3 (en)	2004-08-12	Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
WO2007059341A3 (en)	2007-11-29	Pyrazolothiazole protein kinase modulators
NO20053903D0 (no)	2005-08-22	Nukleotidlipidesterderivater.
ATE418613T1 (de)	2009-01-15	Antimikrobielle zusammensetzungen
WO2003039484A3 (en)	2004-08-12	Novel compositions and methods for cancer
WO2006015191A3 (en)	2006-11-09	Multicyclic lonidamine analogs